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Abstract The design of novel genes encoding arti¢cial tran-
scription factors represents a powerful tool in biotechnology
and medicine. We have engineered a new zinc ¢nger-based tran-
scription factor, named Blues, able to bind and possibly to mod-
ify the expression of ¢broblast growth factor 4 (FGF-4, K-fgf),
originally identi¢ed as an oncogene. Blues encodes a three zinc
¢nger peptide and was constructed to target the 9 bp DNA
sequence: 5P-GTT-TGG-ATG-3P, internal to the murine FGF-
4 enhancer, in proximity of Sox-2 and Oct-3 DNA binding sites.
Our ¢nal aim is to generate a model system based on arti¢cial
zinc ¢nger genes to study the biological role of FGF-4 during
development and tumorigenesis.
0 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Various strategies have been reported for generating new
arti¢cial transcription factors able to recognize and to modify
the expression of a speci¢c gene of interest [1,2]. The zinc
¢ngers of the class Cys2-His2 appear optimal for this purpose,
thanks to their plasticity and versatility [1^5]. The X-ray crys-
tal structures of the three zinc ¢nger transcription factor
Zif268 bound to its DNA target reveal that each individual
¢nger binds essentially 3 bp of double-stranded DNA,
through speci¢c contacts with the amino-terminal part of
the K-helix (amino acid positions: 31, +3, +6) [6,7]. In par-
ticular, a ‘recognition code’ that relates the amino acids of a
single ¢nger to its associated subsite DNA target has been
proposed for a variety of ¢nger domains [8^14]. Rational
zinc ¢nger design, using the code and/or the selection ap-
proach, permits the production of ¢nger domains with satis-
factory binding properties to target almost any desired se-
quence in the genome [15]. The fusion of the arti¢cial zinc
¢nger DNA binding domain with di¡erent transcriptional reg-
ulatory domains can result in either activation or repression of
the expression of chosen target genes [3,14,16,17]. Several re-
search groups have produced synthetic transcription factors
able to repress the expression of speci¢c oncogenes. Choo and
Klug have constructed a three ¢nger peptide that binds the
unique sequence, 9 bp long, present in the junction of the c-
Abl proto-oncogene and BCR gene, in acute lymphoblastic
leukemia [18]. Barbas and colleagues have recently realized
¢nger chimeric proteins able to modulate the expression of
the genomic loci of erb-2 and erb-3 genes, both involved in
human cancers [19,20].
The ¢broblast growth factor 4 (FGF-4) was originally iden-
ti¢ed as an oncogene, by transfection experiments of DNA
derived from Kaposi’s sarcoma [21,22]. The mechanism of
activation of the proto-oncogene is due to unregulated expres-
sion, rather than the production of an abnormal protein [23].
Generally, a gene encoding a growth factor can potentially
behave as an oncogene in any cell type that does not strictly
regulate its expression. The physiological expression of the
murine proto-oncogene FGF-4, silent in the adult, is restricted
to early embryonic stages, speci¢cally in the inner cell mass of
blastocyst and later in speci¢c embryonic tissues [24^26]. The
growth factor FGF-4 has been shown to be essential for post-
implantation mouse development by knock-out experiments
[27]. Assuming that FGF-4 expression patterns in human
and mouse are similar, no expression would be expected in
normal human adult tissues. Nonetheless, expression of FGF-
4 and INT2 (FGF-3) has been detected in Kaposi’s sarcoma,
whose cytogenetic and molecular bases are still poorly under-
stood. Genomic co-ampli¢cation of these two genes has also
been reported in di¡erent human malignancies, including
breast cancer and melanoma [28].
Accordingly to its physiological pattern of expression,
FGF-4 is observed in murine embryonic stem cells and em-
bryonic carcinoma (EC) cell lines. FGF-4 is absent in HeLa
and NIH3T3 cell lines [24]. In a mouse F9 teratocarcinoma
cell line, FGF-4 is switched o¡ upon di¡erentiation. In EC
cells FGF-4 expression requires the synergistic interaction be-
tween the two transcription factors Oct-3 and Sox-2, on the
FGF-4 enhancer [29^32]. In particular, Sox-2 and Oct-3 bind
to adjacent cis-acting elements to form a ternary protein^
DNA complex [30]. The FGF-4 enhancer, located in the 3P
untranslated region, is conserved both in human and murine
genes and is able to drive transcription starting from both
homologous and heterologous promoters [24].
Here, we demonstrate that the engineered gene Blues en-
codes a zinc ¢nger protein (pBlues) that speci¢cally binds its
chromosomal DNA target. The Blues gene product is able to
modulate transcription of a test gene, from the FGF-4 en-
hancer.
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2. Materials and methods
2.1. Constructs
The construction of the Blues gene was obtained as described by
Corbi et al. [12^14]. Brie£y, using as a model the zinc ¢nger backbone
of the Zif268 gene [33], we synthesized two overlapping oligonucleo-
tides, named Blues-5P (154 nt) and Blues-3P (160 nt) respectively. The
resulting Blues DNA fragment was cloned both into the pRK5-HA
mammalian expression vector (pRK5-Blues), containing the hemag-
glutinin (HA) tag sequences, and into the pGEX-4T-3 bacterial ex-
pression vector (GST-Blues) (Pharmacia). To construct the pRK5-
Krab-Blues expression vector the Blues zinc ¢nger domain was cloned
at the 5P end of the Kruppel-associated box A (KRAB A) repression
domain derived from the murine Zfp60 gene (amino acids 1^54, Gen-
Bank accession number U48721) (Fig. 4A) [34]. The reporter plasmid
pGL3PrBTS(5n) was constructed cloning ¢ve copies of monomer BTS
sequence at the 5P end of the SV40 promoter into pGL3 Promoter
vector (Promega).
2.2. Expression of bacterial recombinant fusion protein
The recombinant GST-Blues protein was expressed in BL21(DE3)
host bacteria by isopropyl-L-D-thiogalactose induction and puri¢ed
using glutathione-agarose beads as previously described [14].
2.3. Electrophoretic mobility shift assay (EMSA)
EMSA was performed as previously described [14]. The oligonu-
cleotide probes contained either one or two copies of BTS target
(underlined): 5P-TTTCGCTCGGGCTCGAGGGTTTGGATGGGC-
TCGAGGTCAGG-3P and 5P-TCGACGGTTTGGATGGGCTCGA-
GGGTTTGGATGGGCTCGAGG. The DNA sequences of the mu-
tagenized oligonucleotides BTSm1, BTSm2 and BTSm3 were: 5P-
TTTCGCTCGGGCTCGAGGACCTGGATGGGCTCGAGGTCA-
GG-3P, 5P-TTTCGCTCGGGCTCGAGGGTTATAATGGGCTCG-
AGGTCAGG-3P and 5P-TTTCGCTCGGGCTCGAGGGTTTGG-
TTTGGCTCGAGGTCAGG-3P respectively. The oligos used in
EMSA were labeled using T4 polynucleotide kinase. Supershift of
Blues protein was obtained adding 3 Wl of mouse monoclonal anti-
body (clone 12CA5) to the HA peptide derived from the in£uenza
hemagglutinin protein (Roche Diagnostic).
To measure the apparent dissociation constant [12^14] (Kd) of the
GST-Blues/BTS complex we performed EMSA [14]. The radioactive
signals were visualized by autoradiography and quantitated by Image-
Quant software (Molecular Dynamics) and the data were analyzed
with the KaleidaGraph program (Abelbeck Software). The Kd value
was determined as an average of three separate studies. Small-scale
nuclear extracts from mammalian cell lines were prepared as previ-
ously described [14]. EMSAs were performed using 2^5 Wg of proteins.
2.4. Cell lines, transfections and reporter gene assay
Mouse ¢broblast NIH3T3 and mouse EC F9 cell lines were grown
in Dulbecco’s modi¢ed Eagle’s medium supplemented with 10% fetal
calf serum. The transient transfection experiments were carried out
using Lipofectamine and Plus reagent (Gibco BRL) according to the
manufacturer’s instructions. Cell extracts were prepared and assayed
for luciferase (LUC) activity, according to the manufacturer’s instruc-
tions (Promega), using the luminometer Berthold LB9506. Total pro-
tein quanti¢cation in the extracts was determined by the Bradford
assay and LUC activity of equal amount of proteins was determined
and normalized for L-galactosidase activity.
2.5. Chromatin immunoprecipitation assay (ChIP)
Chromatin immunoprecipitation [35,36] was performed using the
ChiP assay kit (Upstate Biotechnology). Approximately 2 million cells
transfected (cell transfection e⁄ciency was about 60%) with pRK5-
Blues were cross-linked with 1% formaldehyde, for 10 min, at 37‡C
and lysed. The cell lysate was sonicated on ice, resulting in a DNA
fragment of length approximately 500 bp. Immunoprecipitation was
performed overnight, with 5 Wg of anti-HA antibody. DNA represent-
ing 0.005% of the sonicated chromatin solution (input) and 10% of the
immunoprecipitated sonicated chromatin solution were ampli¢ed us-
ing murine FGF-4 enhancer-speci¢c primers (FGF-4enhF 5P-CT-
GGGAGACTTCTGAGCAACCTCC-3P and FGF-4enhR 5P-ATT-
GTCCTGTGAGCCACCAGACAG-3P). Polymerase chain reaction
(PCR) conditions were: 95‡C for 5 min, followed by 40 cycles at
94‡C for 45 s, 62‡C for 30 s, 72‡C for 30 s.
3. Results
3.1. Structure of the Blues gene
The Blues gene was constructed to produce a protein
(pBlues) with the highest probability of targeting the DNA
sequence: 5P-GTT-TGG-ATG-3P, that we named Blues target
sequences (BTS) (Fig. 1A). BTS is present in the 3P enhancer
region of the mouse FGF-4 gene [24] (Fig. 1B). The Blues
gene is 282 bp long, encoding three zinc ¢nger domains
(Fig. 1A). The zinc ¢nger backbone used to construct Blues
was related to both the Zif268 natural gene product [33] and
the Jazz arti¢cial gene product [14]. The pBlues DNA binding
capacity was speci¢ed on the basis of the code signatures.
Each ¢nger domain appears to behave as an independent
DNA binding module, making contacts with three adjacent
base pairs on one DNA strand [7]. In order to obtain Blues
protein, the second and the third zinc ¢ngers of the Zif268
gene have been modi¢ed at positions 31, +3, +6 of the K-
helix [1,7]. The resulting pBlues structure was the following:
Fig. 1. Schematic representation of Blues and its DNA target. A:
Nucleotide and amino acid sequences of the synthetic three zinc ¢n-
ger gene Blues (accession number AY364163). Amino acid residues
used in the critical positions of the K-helix are indicated in bold
characters. The amino acid stretches composing the K-helix regions
present in each ¢nger domain are numbered and underlined. The
putative Blues DNA target sequence (BTS) is indicated in bold
characters. B: Nucleotide sequence of the murine FGF-4 3P en-
hancer region. Main transcription factor binding sites are under-
lined. The Blues target sequence is boxed and partially overlaps
SOX and OCT binding sites.
FEBS 28089 16-2-04
V. Libri et al./FEBS Letters 560 (2004) 75^8076
the third ¢nger domain, at the carboxy-terminal region, was
constructed to recognize the DNA triplet 5P-GTT-3P, the sec-
ond ¢nger recognized the triplet 5P-TGG-3P, ¢nally the ¢rst
¢nger recognized the triplet 5P-ATG-3P (Fig. 1A).
3.2. GST-Blues DNA binding properties
To test the binding properties of pBlues toward its putative
DNA target sequence, we performed EMSAs using the fusion
protein GST-Blues, produced and puri¢ed in Escherichia coli.
Fig. 2A shows an evident shift of the oligonucleotide probe
containing the double-stranded BTS target in the presence of
increasing amounts of GST-Blues (lane 1^4). To obtain a
more subtle de¢nition of the contribution of each Blues ¢nger
to DNA binding speci¢city, oligonucleotide target mutants,
with only one of the DNA triplets changed (lanes 5^8, 9^12,
13^16 respectively), were assayed in the same EMSA. As
shown in Fig. 2A, GST-Blues binds the BTS probe with af-
¢nity and speci¢city strikingly higher than the BTS mutants:
BTSm1, BTSm2 and BTSm3. In the presence of BTSm1 and
BTSm3 probes, whose mutation a¡ects the ¢rst and third
triplet respectively, pBlues DNA binding is dramatically com-
promised, while in the presence of BTSm2 the shift is com-
pletely lost. This is consistent with the crucial role of the
target central DNA triplet in the binding of a three zinc ¢nger
protein. Moreover, to further con¢rm the pBlues speci¢city
toward BTS, we have assayed GST-Blues in EMSA using as
probe other DNA target sequences recognized by both natural
zinc ¢nger proteins (Sp1 and Zif268) and the arti¢cial zinc
Fig. 2. DNA binding speci¢city of GST-Blues protein. A: Contribution to DNA binding activity of each Blues zinc ¢nger domain analyzed by
EMSA. Increasing amounts of GST-Blues protein were incubated with equal amount of labeled BTS (lanes 1^4) and with labeled mutant tar-
gets (lanes 5^16). The mutated triplets in each mutant target are indicated in lowercase. B: EMSA performed with equal amount of following
labeled probes: BTS (lanes 1, 2), Zif268 (lanes 3, 4), Jazz (lanes 5, 6) and Sp1 (lanes 7, 8).
Fig. 3. Determination of the dissociation constant (Kd) by EMSA. A: Lanes 1^7 show: 0, 8, 16, 32, 64, 128 and 256 nM of GST-Blues protein
incubated with labeled BTS (top panel); quality control of puri¢ed/eluted GST-Blues protein by Coomassie staining, compared with puri¢ed
commercial bovine serum albumin (bottom panel). B: EMSA-derived curve. The protein concentration is expressed in nM.
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¢nger peptide (Jazz) [14]. As shown in Fig. 2B, in the presence
of GST-Blues (lane 2), the signal of BTS shift is strongly
higher than those obtained with both Jazz and Sp1 targets
(lanes 6 and 8), while with Zif268 target the shift is almost
undetectable (lane 4). To measure the a⁄nity of the GST-
Blues for the BTS target the relative dissociation constant
(Kd) was determined by EMSA performed using increasing
amounts of GST-Blues, combined with a constant amount
of labeled BTS (Fig. 3). In our experimental conditions, we
obtained a Kd of about 75 nM. These data strongly indicate
that GST-Blues e⁄ciently binds its ‘code-programmed’ target.
3.3. Blues expression and DNA binding activity in eukaryotic
cell lines
In order to characterize the biological activity of pBlues, we
expressed the synthetic protein in mammalian cell lines both
as a simple three ¢nger peptide and as a fusion with the tran-
scriptional repression domain Krab (Krab-Blues) (Fig. 4A).
The resulting molecules (pBlues and Krab-Blues) were ex-
pressed in the NIH3T3 cell line as HA-tagged proteins, under
the control of the regulative regions derived from cytomega-
lovirus. By Western blot analysis we checked the expression
and the correct size of Blues and Krab-Blues proteins (Fig.
4B). To study the DNA binding properties of pBlues, EMSAs
were performed using cell nuclear extracts derived from
NIH3T3 transiently transfected with the construct expressing
pBlues. In Fig. 4C, the protein present in the extracts bound
to BTS is indicated by an arrowhead (lane 5). The identity of
the protein complexed with BTS was further con¢rmed by
both the presence of a pBlues supershift and a partial disap-
pearance of pBlues shift, when the HA tag antibody was
added to the reaction mixture (lane 3).
3.4. Chromatin immunoprecipitation of Blues
The e¡ectiveness of pBlues in speci¢c DNA binding led us
to employ a more direct strategy to investigate the accessibil-
ity of pBlues to the chromatin infrastructure. To this end, a
ChIP assay was performed in F9 cells. The Blues expression
Fig. 4. DNA binding activity of pBlues in mammalian cell lines. A: Schematic representation of the chimeric Blues and Krab-Blues proteins.
The SV40 nuclear localization signal (NLS) and the HA epitope are indicated. B: Western blot analysis of Blues and Krab-Blues proteins, pre-
pared from total extracts of transiently transfected NIH3T3 cells and revealed using 12CA5 monoclonal antibody. C: EMSA of pBlues ex-
pressed in NIH3T3 cells. D: pBlues chromatin immunoprecipitation, performed in transfected F9 cells, using either 12CA5 monoclonal anti-
body/protein A-agarose beads or only protein A-agarose beads as a control (no-ab). Immunoprecipitates from each sample were analyzed by
PCR. A sample representing linear ampli¢cation of the total input chromatin (input) was included in the PCR as a control (lane 1).
Fig. 5. Trans-repression of pGL3PrBTS(5n) construct by Krab-Blues
and Blues proteins. A: Schematic representation of the LUC con-
struct containing ¢ve copies of the BTS, upstream of the SV40 pro-
moter. B: Histograms show fold repression of the pGL3PrBTS(5n)
or pGL3Pr reporter constructs (0.1 Wg), obtained upon co-transfec-
tion with either Blues (0.8 Wg) or Krab-Blues (0.2 Wg and 0.8 Wg)
expression vectors in NIH3T3 cells. The data are presented as the
meansWS.D. of three independent transient transfection experiments
performed in duplicate.
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construct was transiently transfected and after cross-linking
and immunoprecipitation with speci¢c antibody, the FGF-4
enhancer, containing the BTS sequence, was PCR-ampli¢ed.
As shown in Fig. 4D pBlues is able to bind its target sequence
at the endogenous chromosomal site.
3.5. Blues transcriptional activity
The next step was to test whether Krab-Blues chimeric
protein was able to modulate the expression of a test gene
driven by the region of FGF-4 enhancer responsible for Blues
binding. To this end Blues and Krab-Blues expression con-
structs were separately transfected into NIH3T3 cells with
the LUC reporter construct pGL3PrBTS(5n) (Fig. 5A). As
shown in Fig. 5B, Krab-Blues represses the LUC activity
of pGL3PrBTS(5n), by about two- to three-fold in a dose-
dependent manner. As expected, the co-transfection of
pGL3PrBTS(5n) with Blues containing only the zinc ¢nger
region as well as the co-transfection of the control vector
(pGL3Pr) with either Blues or Krab-Blues did not give any
LUC repression activity. These results, together with the
DNA binding data reported above, strongly support the no-
tion that Krab-Blues chimeric protein is able to repress tran-
scription from a test gene through speci¢c binding to the 9 bp
BTS present in the murine FGF-4 enhancer.
4. Discussion
The possibility of re-programming the expression of speci¢c
genes represents a promising tool in basic science, biotechnol-
ogy and medicine. In particular, disease-related genes can be
either turned o¡ or enhanced for the purpose of treating con-
ditions such as cancer or viral infection. An important tech-
nology for achieving this goal is the rational design of zinc
¢ngers based on the recognition code. Using the available list
of the amino acid^base contacts dictated by the recognition
code, we have realized several synthetic zinc ¢nger genes [12^
14]. Here we report the design, construction and functional
characterization of the novel arti¢cial gene, Blues, whose
product is able to bind and to repress transcription from
the 3P enhancer of the FGF-4 gene. Using di¡erent ap-
proaches, we have shown that pBlues is able to recognize its
DNA target. The complex pBlues/target is stable and its Kd is
comparable to the values obtained for other arti¢cial and
natural zinc ¢nger proteins [12^14,37,38]. The calibration of
the correct degree of DNA binding a⁄nity and speci¢city is
one of the crucial matters in designing and selecting synthetic
zinc ¢nger peptides [7,16]. We demonstrated that pBlues rec-
ognizes its 9 bp programmed DNA target with a proper bal-
ance between a⁄nity and speci¢city. Statistically assuming
random base distribution, a 9 bp long DNA target sequence
should be present in the human genome (V3.5U109 bp)
about 1.3U104 times. Therefore, for a target sequence to be
unique in the human genome requires a length at least 16 bp
[14]. Of course, since the chromatin infrastructure protects
most of the genome from DNA binding proteins, only a small
portion of their potential sites is accessible, so that the target
length required for speci¢c recognition in the chromosomal
context can be much shorter. Signi¢cantly, the genomic locus
of the FGF-4 enhancer, containing the Blues target sequence,
includes the binding sites of two other well-characterized tran-
scription factors, Sox-2 and Oct-3, suggesting for this region
an accessible conformation of the chromatin. By ChIP experi-
ments, we con¢rmed the e¡ective access of pBlues to active
chromatin of the FGF-4 enhancer region. This last result,
together with the transcriptional data, is particularly promis-
ing in view of conducting an in vivo study of the e¡ect on
transcription of FGF-4 growth factor, regulated by a Blues
module fused to chosen regulatory domains. The ability to
modulate the expression of the FGF-4 gene at will represents
a powerful tool to shed light on the role of FGF-4 in tumori-
genesis/angiogenesis and on its multiple role during develop-
ment. Furthermore, re-programmed expression of FGF-4
could have tremendous therapeutic and biological applica-
tions.
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